How it lives in boiling acid offers template for delivering gene therapy
By unlocking the secrets of a bizarre virus that survives in nearly boiling acid, scientists at the University of Virginia School of Medicine have found a blueprint for battling human disease using DNA clad in near-indestructible armor.
“What’s interesting and unusual is being able to see how proteins and DNA can be put together in a way that’s absolutely stable under the harshest conditions imaginable,” said Edward H. Egelman, PhD, of the UVA Department of Biochemistry and Molecular Genetics. “We’ve discovered what appears to be a basic mechanism of resistance – to heat, to desiccation, to ultraviolet radiation. And knowing that, then, we can go in many different directions, including developing ways to package DNA for gene therapy.”
Finding effective packaging for DNA delivery is important because the human body has many ways to degrade and remove foreign DNA – that’s how it combats viruses. But that protective mechanism becomes a major obstacle for doctors seeking to use genes to battle disease. Creating an impenetrable packaging would overcome that problem, and this strange virus offers a promising template.
The virus, SIRV2, infects a microscopic organism known as Sulfolobus islandicus that lives in what Egelman described as “extremely unusual” conditions: acidic hot springs where temperatures top 175 degrees Fahrenheit. The research identified surprising similarities between the SIRV2 virus and the spores bacteria form to survive in inhospitable environments. “Some of these spores are responsible for very, very horrific diseases that are hard to treat, like anthrax. So we show in this paper that this virus actually functions in a similar way to some of the proteins present in bacterial spores,” he said. Spores are also formed by C. difficile, which now accounts for approximately 30,000 deaths per year in the U.S. and has been classified by the Centers for Disease Control and Prevention as having a threat level of “urgent.” “Understanding how these bacterial spores work gives us potentially new abilities to destroy them,” Egelman said. “Having this basic scientific research leads in many, many directions, most of which are impossible to predict, in terms of what the implications are going to be.”
Read more: Nearly indestructible virus yields tool to treat diseases
The Latest on: Gene Therapy
[google_news title=”” keyword=”Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene Therapy
- US Approves Gene Therapy Treatment For Hemophiliaon April 26, 2024 at 11:04 am
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.
- Scientists report that new gene therapy slows down amyotrophic lateral sclerosis disease progressionon April 26, 2024 at 9:09 am
There has been a breakthrough in the research on the disease amyotrophic lateral sclerosis (ALS). Scientists at Umeå University report that the disease progression in a patient with a particularly ...
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
- FDA Approves Second Gene Therapy for Hemophilia Bon April 26, 2024 at 7:38 am
Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.
- Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per doseon April 26, 2024 at 7:19 am
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. | Ten years after dipping its toe ...
- FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia Bon April 26, 2024 at 6:00 am
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
- FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorderon April 26, 2024 at 4:02 am
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
- US FDA approves Pfizer's gene therapy for rare bleeding disorderon April 26, 2024 at 3:17 am
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a ...
- Researchers publish final results of key clinical trial for gene therapy for sickle cell diseaseon April 25, 2024 at 6:14 am
In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY ...
- 2025 Cell & Gene Therapy Reimbursement Outlookon April 24, 2024 at 1:00 pm
CMS proposed Medicare’s CGT reimbursement policy matches Medicaid’s sickle cell disease policy, forming a unified government approach.
via Bing News